论文部分内容阅读
目的:观察倍他乐克联合卡托普利治疗小儿高原性心脏病的临床疗效。方法:45例高原性心脏病患儿随机分为对照组和治疗组,23例对照组患儿给予常规吸氧、利尿、强心等抗心力衰竭治疗,22例治疗组患儿在常规治疗基础上加用倍他乐克和卡托普利,两组疗程均为6个月。观察两组治疗后心率、右室射血分数(LVEF)、平均肺动脉压(mPAP)、左室射血分数(LVEF)改善情况。结果:治疗组总有效率为86.4%高于对照组的56.5%(P<0.05),治疗组心率、RVEF、mPAP、LVEF改善情况优于对照组,差异均有统计学意义(P<0.05和P<0.01)。结论:高原性心脏病患儿服用倍他乐克和卡托普利能改善心功能,提高生活质量,改善预后,可作为治疗小儿高原性心脏病的治疗药物。
Objective: To observe the clinical efficacy of metoprolol combined with captopril in the treatment of children with high altitude heart disease. Methods: Forty-five patients with high altitude heart disease were randomly divided into control group and treatment group. Twenty-three control subjects were given conventional oxygen therapy, diuretic therapy and cardiorespiratory failure. 22 children in treatment group were treated with routine therapy Add Betaloc and Captopril, the two groups were treated for 6 months. The improvement of heart rate, right ventricular ejection fraction (LVEF), mean pulmonary arterial pressure (mPAP) and left ventricular ejection fraction (LVEF) were observed in both groups. Results: The total effective rate was 86.4% in the treatment group and 56.5% in the control group (P <0.05). The improvement of heart rate, RVEF, mPAP and LVEF in the treatment group was better than that in the control group P <0.01). Conclusion: Betaloc and Captopril can improve heart function, improve quality of life and improve prognosis in children with cardiopulmonary heart disease. It may be used as a therapeutic drug for treating heart disease in children with high altitude heart disease.